Mark Kirby

2.4k total citations
28 papers, 962 citations indexed

About

Mark Kirby is a scholar working on Endocrinology, Diabetes and Metabolism, Cellular and Molecular Neuroscience and Oncology. According to data from OpenAlex, Mark Kirby has authored 28 papers receiving a total of 962 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Endocrinology, Diabetes and Metabolism, 13 papers in Cellular and Molecular Neuroscience and 13 papers in Oncology. Recurrent topics in Mark Kirby's work include Peptidase Inhibition and Analysis (13 papers), Diabetes Treatment and Management (13 papers) and Neuropeptides and Animal Physiology (10 papers). Mark Kirby is often cited by papers focused on Peptidase Inhibition and Analysis (13 papers), Diabetes Treatment and Management (13 papers) and Neuropeptides and Animal Physiology (10 papers). Mark Kirby collaborates with scholars based in United States, Germany and Australia. Mark Kirby's co-authors include Lawrence G. Hamann, Mark D. Gorrell, Denise Yu, Jovita Marcinkeviciene, W. Jonathan Lederer, Carolyn A. Weigelt, Aiying Wang, William J. Metzler, Watt W. Webb and Heping Cheng and has published in prestigious journals such as Journal of Medicinal Chemistry, The Journal of the Acoustical Society of America and Biochimica et Biophysica Acta (BBA) - Biomembranes.

In The Last Decade

Mark Kirby

27 papers receiving 941 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Mark Kirby United States	17	409	379	319	221	185	28	962
Aleksandr Petrov United States	17	470 1.1×	361 1.0×	247 0.8×	241 1.1×	111 0.6×	50	931
Edwin B. Villhauer United States	11	602 1.5×	301 0.8×	504 1.6×	336 1.5×	236 1.3×	16	1.1k
Nam Sook Kang South Korea	20	140 0.3×	526 1.4×	185 0.6×	84 0.4×	232 1.3×	97	1.2k
Andreas Evers Germany	21	281 0.7×	1.1k 3.0×	121 0.4×	280 1.3×	170 0.9×	55	1.6k
Bhumika Patel India	12	102 0.2×	330 0.9×	215 0.7×	66 0.3×	151 0.8×	36	724
Bruce G. Szczepankiewicz United States	19	80 0.2×	904 2.4×	155 0.5×	34 0.2×	386 2.1×	32	1.4k
Emma R. Parmee United States	21	317 0.8×	731 1.9×	174 0.5×	175 0.8×	1.0k 5.5×	36	1.8k
Samuel Chackalamannil United States	24	60 0.1×	504 1.3×	68 0.2×	104 0.5×	848 4.6×	75	1.7k
L. McLean United States	10	84 0.2×	539 1.4×	63 0.2×	82 0.4×	56 0.3×	13	805
Michael Lisurek Germany	19	252 0.6×	550 1.5×	119 0.4×	21 0.1×	155 0.8×	28	854

Countries citing papers authored by Mark Kirby

Since Specialization

Citations

This map shows the geographic impact of Mark Kirby's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Kirby with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Kirby more than expected).

Fields of papers citing papers by Mark Kirby

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Kirby. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Kirby. The network helps show where Mark Kirby may publish in the future.

Co-authorship network of co-authors of Mark Kirby

This figure shows the co-authorship network connecting the top 25 collaborators of Mark Kirby. A scholar is included among the top collaborators of Mark Kirby based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark Kirby. Mark Kirby is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ibhadode, Osezua, et al.. (2023). Topological fidelity of additively manufactured AlSi10Mg gyroid structures. Journal of Manufacturing Processes. 108. 671–684. 3 indexed citations

Xiao, Yue, Lichun Jiang, Zhi‐Ming Ding, et al.. (2018). A circulating microRNA signature as noninvasive diagnostic and prognostic biomarkers for nonalcoholic steatohepatitis. BMC Genomics. 19(1). 188–188. 38 indexed citations

Zhao, Guohua, Chet Kwon, Aiying Wang, et al.. (2013). Substituted piperidinyl glycinyl 2-cyano-4,5-methano pyrrolidines as potent and stable dipeptidyl peptidase IV inhibitors. Bioorganic & Medicinal Chemistry Letters. 23(6). 1622–1625. 11 indexed citations

Ye, Xiang‐Yang, David Yoon, Akbar Nayeem, et al.. (2013). Synthesis and structure–activity relationship of 2-adamantylmethyl tetrazoles as potent and selective inhibitors of human 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1). Bioorganic & Medicinal Chemistry Letters. 24(2). 654–660. 14 indexed citations

Harstad, Eric B., Jonathan S. Rosenblum, Mark D. Gorrell, et al.. (2013). DPP8 and DPP9 expression in cynomolgus monkey and Sprague Dawley rat tissues. Regulatory Peptides. 186. 26–35. 15 indexed citations

Wang, Aiying, Charles R. Dorso, Lisa M. Kopcho, et al.. (2012). Potency, selectivity and prolonged binding of saxagliptin to DPP4: maintenance of DPP4 inhibition by saxagliptin in vitro and ex vivo when compared to a rapidly-dissociating DPP4 inhibitor. BMC Pharmacology. 12(1). 2–2. 49 indexed citations

Xu, Xiaohui, Huidong Gu, Lisa J. Christopher, et al.. (2012). Liquid chromatography and tandem mass spectrometry method for the quantitative determination of saxagliptin and its major pharmacologically active 5-monohydroxy metabolite in human plasma: Method validation and overcoming specific and non-specific binding at low concentrations. Journal of Chromatography B. 889-890. 77–86. 32 indexed citations

Ye, Xiang‐Yang, Stephanie Chen, Akbar Nayeem, et al.. (2011). Design, synthesis, and SAR studies of novel polycyclic acids as potent and selective inhibitors of human 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD-1). Bioorganic & Medicinal Chemistry Letters. 21(22). 6699–6704. 11 indexed citations

Wang, Wei, Pratik Devasthale, Aiying Wang, et al.. (2011). 7-Oxopyrrolopyridine-derived DPP4 inhibitors—mitigation of CYP and hERG liabilities via introduction of polar functionalities in the active site. Bioorganic & Medicinal Chemistry Letters. 21(22). 6646–6651. 15 indexed citations

10.

Meng, Wei, Aberra Fura, Thomas Harrity, et al.. (2010). Synthesis and SAR of azolopyrimidines as potent and selective dipeptidyl peptidase-4 (DPP4) inhibitors for type 2 diabetes. Bioorganic & Medicinal Chemistry Letters. 20(15). 4395–4398. 47 indexed citations

11.

Fura, Aberra, Ashish K. Khanna, Viral Vyas, et al.. (2009). Pharmacokinetics of the Dipeptidyl Peptidase 4 Inhibitor Saxagliptin in Rats, Dogs, and Monkeys and Clinical Projections. Drug Metabolism and Disposition. 37(6). 1164–1171. 86 indexed citations

12.

Metzler, William J., Joseph Yanchunas, Carolyn A. Weigelt, et al.. (2008). Involvement of DPP‐IV catalytic residues in enzyme–saxagliptin complex formation. Protein Science. 17(2). 240–250. 103 indexed citations

13.

Atwal, Karnail S., Steven V. O’Neil, Saleem Ahmad, et al.. (2006). Synthesis and biological activity of 5-aryl-4-(4-(5-methyl-1H-imidazol-4-yl)piperidin-1-yl)pyrimidine analogs as potent, highly selective, and orally bioavailable NHE-1 inhibitors. Bioorganic & Medicinal Chemistry Letters. 16(18). 4796–4799. 33 indexed citations

14.

Kopcho, Lisa M., Young B. Kim, Aiying Wang, et al.. (2005). Probing prime substrate binding sites of human dipeptidyl peptidase-IV using competitive substrate approach. Archives of Biochemistry and Biophysics. 436(2). 367–376. 3 indexed citations

15.

Kim, Young B., Lisa M. Kopcho, Mark Kirby, et al.. (2005). Mechanism of Gly-Pro-pNA cleavage catalyzed by dipeptidyl peptidase-IV and its inhibition by saxagliptin (BMS-477118). Archives of Biochemistry and Biophysics. 445(1). 9–18. 62 indexed citations

16.

Magnin, David R., Prakash C. Taunk, James G. Robertson, et al.. (2005). Seco-prolinenitrile inhibitors of dipeptidyl peptidase IV define minimal pharmacophore requirements at P1. Bioorganic & Medicinal Chemistry Letters. 16(6). 1731–1734. 3 indexed citations

17.

Zhao, Guohua, Prakash C. Taunk, David R. Magnin, et al.. (2005). Diprolyl nitriles as potent dipeptidyl peptidase IV inhibitors. Bioorganic & Medicinal Chemistry Letters. 15(18). 3992–3995. 19 indexed citations

18.

Ahmad, Saleem, Khehyong Ngu, Donald W. Combs, et al.. (2003). Aminoimidazoles as bioisosteres of acylguanidines: novel, potent, selective and orally bioavailable inhibitors of the sodium hydrogen exchanger isoform-1. Bioorganic & Medicinal Chemistry Letters. 14(1). 177–180. 18 indexed citations

19.

Lokuta, Andrew J., Mark Kirby, S T Gaa, W. Jonathan Lederer, & Terry B. Rogers. (1994). On Establishing Primary Cultures of Neonatal Rat Ventricular Myocytes for Analysis Over Long Periods. Journal of Cardiovascular Electrophysiology. 5(1). 50–62. 30 indexed citations

20.

Kirby, Mark, R. W. Hadley, & W. Jonathan Lederer. (1994). Measurement of intracellular Ca2+ concentration using Indo-1 during simultaneous flash photolysis to release Ca2+ from DM-nitrophen. Pflügers Archiv - European Journal of Physiology. 427(1-2). 169–177. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact